Nilo S. Azad

Nilo S. Azad

Oncology
201 North Broadway Street, Viragh BLDG 5th FL
Viragh BLDG 5th FL
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 165 publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine
Published: September 02, 2026

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

Journal: The New England journal of medicine
Published: June 01, 2026

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Journal: The New England journal of medicine
Published: May 06, 2026

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Journal: Nature communications
Published: April 15, 2026

Liver-Directed Therapy for Colorectal Cancer: Where Are We Now?

Liver-Directed Therapy for Colorectal Cancer: Where Are We Now?

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: January 26, 2026

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 19, 2026

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Journal: Cancer discovery
Published: December 31, 2025

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Journal: Nature communications
Published: December 02, 2025

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025

Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.

Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 01, 2025

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.

Journal: NPJ precision oncology
Published: July 18, 2025

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.

Journal: EBioMedicine
Published: July 03, 2025
Showing 1-12 of 165

Last Updated: 09/26/2026